Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-060084
Filing Date
2025-04-29
Accepted
2025-04-29 16:03:56
Documents
16
Period of Report
2025-05-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A nmra-20250429.htm   iXBRL DEF 14A 1011917
2 GRAPHIC img236770955_0.jpg GRAPHIC 37470
3 GRAPHIC img236770955_1.jpg GRAPHIC 259594
4 GRAPHIC img236770955_2.jpg GRAPHIC 225512
  Complete submission text file 0000950170-25-060084.txt   2607507

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20250429.xsd EX-101.SCH 7930
19 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20250429_htm.xml XML 5782
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41802 | Film No.: 25887053
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)